Clinical trial
Safety and Efficacy of MBI 226 for the Prevention of Central Venous…
NCT00027248 · BioWest Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00027248 |
|---|---|
| Title | Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections |
| Official title | Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization |
| Lead sponsor | BioWest Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sepsis, Bacteremia, Fungemia |
| Intervention type | Drug |
| Interventions | MBI 226 |
| Enrollment | 1,400 |
| Start date | Sep 1, 2000 |
| Completion | Jul 1, 2003 |
| First posted | Nov 30, 2001 |
| Last update posted | Sep 14, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: